Corbus 15min chart indicates bearish sentiment with MACD Death Cross and Marubozu.

Corbus's 15-minute chart has recently exhibited a MACD Death Cross and a bearish Marubozu pattern on September 26, 2025 at 10:30. This indicates that the stock price has the potential to continue trending downward, with sellers dominating the market and bearish momentum likely to persist.

Corbus Pharmaceuticals (CRBP) has recently exhibited bearish technical indicators on its 15-minute chart, specifically a MACD Death Cross and a Marubozu pattern, on September 26, 2025, at 10:30. These indicators suggest that the stock price may continue to trend downward, with sellers dominating the market and bearish momentum likely to persist Corbus Pharmaceuticals Holdings, Inc. $CRBP Shares Purchased by Atle Fund Management AB^[2].

The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a potential change in the stock's trend from bullish to bearish. The Marubozu pattern, characterized by a long white or black candle with no shadows, suggests strong momentum in the direction of the candle, in this case, a bearish trend.

Additionally, Corbus Pharmaceuticals has seen a decrease in its stock price, trading down $0.12 during mid-day trading on Friday, September 12, 2025, to $11.50 Corbus Pharmaceuticals Holdings, Inc. $CRBP Shares Purchased by Atle Fund Management AB^[2]. The company's market cap stands at $140.93 million, with a price-to-earnings ratio of -2.42 and a beta of 3.08 Corbus Pharmaceuticals Holdings, Inc. $CRBP Shares Purchased by Atle Fund Management AB^[2]. The stock has a 1-year low of $4.64 and a 1-year high of $23.33 Corbus Pharmaceuticals Holdings, Inc. $CRBP Shares Purchased by Atle Fund Management AB^[2].

Institutional investors have shown interest in Corbus Pharmaceuticals, with Atle Fund Management AB increasing its stake by 78.6% in the second quarter, owning approximately 1.43% of the company valued at $1.21 million after acquiring 77,278 shares Corbus Pharmaceuticals Holdings, Inc. $CRBP Shares Purchased by Atle Fund Management AB^[2]. Other large investors such as Deutsche Bank AG, Two Sigma Advisers LP, Stonepine Capital Management LLC, Nuveen LLC, and AlphaQuest LLC have also modified their holdings in the company Corbus Pharmaceuticals Holdings, Inc. $CRBP Shares Purchased by Atle Fund Management AB^[2].

Analysts have generally maintained a positive outlook on Corbus Pharmaceuticals, with several firms issuing "buy" ratings and target prices ranging up to $56.00, indicating strong potential growth Corbus Pharmaceuticals Holdings, Inc. $CRBP Shares Purchased by Atle Fund Management AB^[2]. However, the recent technical indicators suggest a potential downturn in the stock's price.